Skip to main content Accessibility help
×
Hostname: page-component-77c89778f8-swr86 Total loading time: 0 Render date: 2024-07-24T04:09:55.609Z Has data issue: false hasContentIssue false

Chapter 24 - Anemia in the Patient with Cancer

from Section 4 - Secondary Anemias

Published online by Cambridge University Press:  18 April 2018

Edward J. Benz, Jr.
Affiliation:
Dana Farber Cancer Institute
Nancy Berliner
Affiliation:
Brigham and Women's Hospital, Boston
Fred J. Schiffman
Affiliation:
Children's Hospital, Boston
Get access

Summary

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Anemia
Pathophysiology, Diagnosis, and Management
, pp. 172 - 178
Publisher: Cambridge University Press
Print publication year: 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Caro, JJ, Salas, M, Ward, A, Goss, G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91: 22142221.3.0.CO;2-P>CrossRefGoogle Scholar
Ludwig, H, Van Belle, S, Barrett-Lee, P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer. 2004; 40:22932306.CrossRefGoogle ScholarPubMed
Tonia, T, Mettler, A, Robert, N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews. 2012; 12:CD003407.Google ScholarPubMed
Knight, K, Wade, S, Balducci, L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. The American Journal of Medicine. 2004; 116 Suppl 7A:11S26S.Google Scholar
Groopman, JE, Itri, LM. Chemotherapy-induced anemia in adults: incidence and treatment. Journal of the National Cancer Institute. 1999; 91:16161634.CrossRefGoogle ScholarPubMed
Spivak, JL. The anaemia of cancer: death by a thousand cuts. Nature Reviews Cancer. 2005; 5:543555.Google Scholar
Maccio, A, Madeddu, C, Massa, D, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 2005; 106:362367.Google Scholar
Hohaus, S, Massini, G, Giachelia, M, et al. Anemia in Hodgkin’s lymphoma: the role of interleukin-6 and hepcidin. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010; 28:25382543.Google Scholar
Tisi, MC, Bozzoli, V, Giachelia, M, et al. Anemia in diffuse large B cell non-Hodgkin Lymphoma: the role of IL-6, hepcidin and erythropoietin. Leukemia & Lymphoma. 2013.CrossRefGoogle Scholar
Sharma, S, Nemeth, E, Chen, YH, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2008; 14:32623267.Google Scholar
Santos, FP, Alvarado, Y, Kantarjian, H, et al. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer. 2011; 117:982991.Google Scholar
Van Glabbeke, M, Verweij, J, Casali, PG, et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). European Journal of Cancer. 2006; 42:22772285.Google Scholar
Funakoshi, T, Latif, A, Galsky, MD. Risk of hematologic toxicities in cancer patients treated with sunitinib: A systematic review and meta-analysis. Cancer Treatment Reviews. 2013; 39:818830.Google Scholar
Goodnough, LT, Nemeth, E, Ganz, T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010; 116:47544761.Google Scholar
Wright, JR, Ung, YC, Julian, JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2007; 25:10271032.Google Scholar
Smith, RE Jr., Aapro, MS, Ludwig, H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008; 26:10401050.Google Scholar
Khorana, AA, Francis, CW, Blumberg, N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Archives of Internal Medicine. 2008; 168:23772381.Google Scholar
Grant, MD, Piper, M, Bohlius, J, et al. Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update. AHRQ Comparative Effectiveness Reviews. Rockville (MD); 2013.Google Scholar
FDA Briefing Document Oncologic Drugs Advisory Committee. 2008 [accessed May 26, 2017]. Available from: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-01-FDA.pdf.Google Scholar
Bohlius, J, Schmidlin, K, Brillant, C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009; 373:15321542.Google Scholar
Pfeffer, MA, Burdmann, EA, Chen, CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. The New England Journal of Medicine. 2009; 361:20192032.Google Scholar
Henke, M, Laszig, R, Rube, C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003; 362:12551260.Google Scholar
Leyland-Jones, B, Semiglazov, V, Pawlicki, M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23:59605972.Google Scholar
Untch, M, von Minckwitz, G, Konecny, GE, et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer–outcome on prognosis. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2011; 22:19992006.CrossRefGoogle ScholarPubMed
Leyland-Jones, B, Bondarenko, I, Nemsadze, G, et al. A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2016; 34:11971207.CrossRefGoogle ScholarPubMed
McKinney, M, Arcasoy, MO. Erythropoietin for oncology supportive care. Experimental Cell Research. 2011; 317:12461254.CrossRefGoogle ScholarPubMed
Rizzo, JD, Brouwers, M, Hurley, P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010; 116:40454059.Google Scholar
National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Cancer- and Chemotherapy-Induced Anemia, updated November 16, 2016 [accessed May 26, 2017]. Version 2.2017. Available from: www.nccn.org/professionals/physician_gls/pdf/anemia.pdf.Google Scholar
Engert, A, Josting, A, Haverkamp, H, et al. Epoetin alfa in patients with advanced-stage Hodgkin’s lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010; 28:22392245.Google Scholar
Moebus, V, Jackisch, C, Schneeweiss, A, et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. Journal of the National Cancer Institute. 2013; 105:10181026.Google Scholar
Schrijvers, D, De Samblanx, H, Roila, F, E.G.W. Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2010; 21(Suppl)5:v244v247.Google Scholar
Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy: National Institute for Health and Clinical Excellence technology appraisal guidance TA323; 2014 [accessed May 26, 2017]. Available from: www.nice.org.uk/guidance/ta323.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×